1086062-66-9 Usage
Description
GSK2126458 is a potent inhibitor of phosphoinositide 3-kinase isoforms (Kis = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively). It also inhibits mTOR in both mTORC1 and mTORC2 (Kis = 180 and 300 nM, respectively), as well as several common mutant forms of p110α. GSK2126458 is orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models. GSK2126458 positively combines with inhibitors of discoidin domain receptor 1 (DDR1) inhibitor DDR1-IN-1 to suppress the growth of SNU-1040 colorectal cancer cells.
Uses
A highly potent inhibitor of PI3K and the mammalian target of Rapamycin.
Check Digit Verification of cas no
The CAS Registry Mumber 1086062-66-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,6,0,6 and 2 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1086062-66:
(9*1)+(8*0)+(7*8)+(6*6)+(5*0)+(4*6)+(3*2)+(2*6)+(1*6)=149
149 % 10 = 9
So 1086062-66-9 is a valid CAS Registry Number.
1086062-66-9Relevant articles and documents
METHOD OF ADMINISTRATION AND TREATMENT
-
Paragraph 0104, (2013/12/04)
The present invention provides a method of treating a human with cancer comprising detecting at least one mutation in a PIK3CA gene or at least one mutant protein encoded by said PIK3CA gene from at least one first sample from said human and administering to said human an effective amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide or a pharmaceutically acceptable salt thereof in a pharmaceutical composition if said at least one sample has at least one mutant PI3K protein or a mutation in the PIK3CA gene.
